3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Temozolomide
3
gadobenic acid
2
XENP 1595
2
Trastuzumab
2
Sodium Chloride
2
Dexmedetomidine
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
tucatinib
1
tipifarnib
1
sagopilone
1
pembrolizumab
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
gadoteridol
1
elacestrant
1
abemaciclib
1
Tissue Banks
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Radiation
1
RAD1901
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Dasatinib
1
Craniotomy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Diseases
×
RAD1901
×
CNS
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled